RG 10.19 St. Philip Neri School for Delayed Vocations Records, Finding Aid

All physical materials associated with the New England Province Archive are currently held by the Jesuit Archives in St. Louis, MO. Any inquiries about these materials should be directed to the Jesuit Archives . Electronic versions of some items and the descriptions and finding aids to the Archives, which are hosted in CrossWorks, are provided only as a courtesy. The St. Philip Neri School opened in September, 1946 in Boston and a second branch opened in Haverhill, MA in 1949. The school was opened as a school for delayed vocations to the priesthood after World War II. Its purpose was to teach Latin so the students could go on to seminaries, which required a foundation of Latin for acceptance. The Haverhill, MA school closed in 1964 and the Boston, MA school closed in 1969. The School closed due to a dwindling number of students because United States seminaries in the mid-1960s were no longer requiring knowledge of Latin for admission as the liturgy was being conducted in English. The collection consists of yearbooks, deeds & correspondence pertaining to the Haverhill, MA property, course catalogs, correspondence, and a written history of the school. The materials date from the 1940s to the 1960s

BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial.

BACKGROUND: Trials done in infants with low birthweight in west Africa suggest that BCG vaccination reduces all-cause mortality in the neonatal period, probably because of heterologous protection against non-tuberculous infections. This study investigated whether BCG alters all-cause infectious disease morbidity in healthy infants in a different high-mortality setting, and explored whether the changes are mediated via trained innate immunity. METHODS: This was an investigator-blind, randomised, controlled trial done at one hospital in Entebbe, Uganda. Infants who were born unwell (ie, those who were not well enough to be discharged directly home from the labour ward because they required medical intervention), with major congenital malformations, to mothers with HIV, into families with known or suspected tuberculosis, or for whom cord blood samples could not be taken, were excluded from the study. Any other infant well enough to be discharged directly from the labour ward was eligible for inclusion, with no limitation on gestational age or birthweight. Participants were recruited at birth and randomly assigned (1:1) to receive standard dose BCG 1331 (BCG-Danish) on the day of birth or at age 6 weeks (computer-generated randomisation, block sizes of 24, stratified by sex). Investigators and clinicians were masked to group assignment; parents were not masked. Participants were clinically followed up to age 10 weeks and contributed blood samples to one of three immunological substudies. The primary clinical outcome was physician-diagnosed non-tuberculous infectious disease incidence. Primary immunological outcomes were histone trimethylation at the promoter region of TNF, IL6, and IL1B; ex-vivo production of TNF, IL-6, IL-1β, IL-10, and IFNγ after heterologous stimulation; and transferrin saturation and hepcidin levels. All outcomes were analysed in the modified intention-to-treat population of all randomly assigned participants except those whose for whom consent was withdrawn. This trial is registered with the International Standard Randomised Controlled Trial Number registry (#59683017). FINDINGS: Between Sept 25, 2014, and July 31, 2015, 560 participants were enrolled and randomly assigned to receive BCG at birth (n=280) or age 6 weeks (n=280). 12 participants assigned to receive BCG at birth and 11 participants assigned to receive BCG at age 6 weeks were withdrawn from the study by their parents shortly after randomisation and were not included in analyses. During the first 6 weeks of life before the infants in the delayed vaccination group received BCG vaccination, physician-diagnosed non-tuberculous infectious disease incidence was lower in infants in the BCG at birth group than in the delayed group (98 presentations in the BCG at birth group vs 129 in the delayed BCG group; hazard ratio [HR] 0·71 [95% CI 0·53-0·95], p=0·023). After BCG in the delayed group (ie, during the age 6-10 weeks follow-up), there was no significant difference in non-tuberculous infectious disease incidence between the groups (88 presentations vs 76 presentations; HR 1·10 [0·87-1·40], p=0·62). BCG at birth inhibited the increase in histone trimethylation at the TNF promoter in peripheral blood mononuclear cells occurring in the first 6 weeks of life. H3K4me3 geometric mean fold-increases were 3·1 times lower at the TNF promoter (p=0·018), 2·5 times lower at the IL6 promoter (p=0·20), and 3·1 times lower at the IL1B promoter (p=0·082) and H3K9me3 geometric mean fold-increases were 8·9 times lower at the TNF promoter (p=0·0046), 1·2 times lower at the IL6 promoter (p=0·75), and 4·6 times lower at the IL1B promoter (p=0·068), in BCG-vaccinated (BCG at birth group) versus BCG-naive (delayed BCG group) infants. No clear effect of BCG on ex-vivo production of TNF, IL-6, IL-1β, IL-10, and IFNγ after heterologous stimulation, or transferrin saturation and hepcidin concentration, was detected (geometric mean ratios between 0·68 and 1·68; p≥0·038 for all comparisons). INTERPRETATION: BCG vaccination protects against non-tuberculous infectious disease during the neonatal period, in addition to having tuberculosis-specific effects. Prioritisation of BCG on the first day of life in high-mortality settings might have significant public-health benefits through reductions in all-cause infectious morbidity and mortality. FUNDING: Wellcome Trust. TRANSLATIONS: For the Luganda and Swahili translations of the abstract see Supplementary Materials section

Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease

Coronary heart disease treatment with HMG-CoA reductase inhibitors has been very successful. There is increasing interest in adding other lipid lowering therapy, primarily as additional therapy onto HMG-CoA reductase therapy. This paper will examine two of the more popular secondary agents, ezetimibe and niacin, and describe their research data and potential for usefulness in further reducing cardiovascular events

Rationale, design and organization of the delayed antibiotic prescription (DAP) trial: a randomized controlled trial of the eficacy and safety of delayed antibiotic prescribing strategies in the non-complicated acute respiratory tract infections in general practice

Background: Respiratory tract infections are an important burden in primary care and it's known that they are usually self-limited and that antibiotics only alter its course slightly. This together with the alarming increase of bacterial resistance due to increased use of antimicrobials calls for a need to consider strategies to reduce their use. One of these strategies is the delayed prescription of antibiotics. Methods: Multicentric, parallel, randomised controlled trial comparing four antibiotic prescribing strategies in acute non-complicated respiratory tract infections. We will include acute pharyngitis, rhinosinusitis, acute bronchitis and acute exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (mild to moderate). The therapeutic strategies compared are: immediate antibiotic treatment, no antibiotic treatment, and two delayed antibiotic prescribing (DAP) strategies with structured advice to use a course of antibiotics in case of worsening of symptoms or not improving (prescription given to patient or prescription left at the reception of the primary care centre 3 days after the first medical visit). Discussion: Delayed antibiotic prescription has been widely used in Anglo-Saxon countries, however, in Southern Europe there has been little research about this topic. The DAP trial wil evaluate two different delayed strategies in Spain for the main respiratory infections in primary care

Reactive probabilistic programming

International audienceSynchronous modeling is at the heart of programming languages like Lustre, Esterel, or SCADE used routinely for implementing safety critical control software, e.g., fly-bywire and engine control in planes. However, to date these languages have had limited modern support for modeling uncertainty-probabilistic aspects of the software's environment or behavior-even though modeling uncertainty is a primary activity when designing a control system. In this paper we present ProbZelus the first synchronous probabilistic programming language. ProbZelus conservatively provides the facilities of a synchronous language to write control software, with probabilistic constructs to model uncertainties and perform inference-in-the-loop. We present the design and implementation of the language. We propose a measure-theoretic semantics of probabilistic stream functions and a simple type discipline to separate deterministic and probabilistic expressions. We demonstrate a semantics-preserving compilation into a first-order functional language that lends itself to a simple presentation of inference algorithms for streaming models. We also redesign the delayed sampling inference algorithm to provide efficient streaming inference. Together with an evaluation on several reactive applications, our results demonstrate that ProbZelus enables the design of reactive probabilistic applications and efficient, bounded memory inference

Analysis and Characterization of the Hyperchaos Generated by a Semiconductor Laser Subject

Abstract—We characterize the chaotic dynamics of semiconductor lasers subject to either optical or electrooptical feedback modeled by Lang–Kobayashi and Ikeda equations, respectively. This characterization is relevant for secure optical communications based on chaos encryption. In particular, for each system we compute as a function of tunable parameters the Lyapunov spectrum, Kaplan–Yorke dimension and Kolmogorov–Sinai entropy. Index Terms—Chaotic communications, chaotic lasers, delay, feedback